Disease diagnostics entails a variety of laboratory procedures for identifying and quantifying infectious pathogens in test materials such as blood and urine. It’s difficult to make a diagnosis based solely on symptoms because two or more diseases can have identical symptoms, so diagnostic tests are performed to confirm the diagnosis. Diagnostic tests provide rapid and precise results, thereby saving time and providing physicians ample time for treatment.
The global infectious disease diagnostics market is estimated to account for US$ 1,131.4 Mn in terms of value in 2020 and is expected to reach US$ 1,841.2 Mn by the end of 2027.
Global Infectious Disease Diagnostics Market: Drivers
Increasing initiatives to solve diagnostic problems in emerging nations are expected to foster the worldwide infectious disease diagnostics market growth. For example, in January 2018, The Foundation for Innovative New Diagnostics collaborated with Becton, Dickinson, and Company (BD), Fondation Botnar, the Global Antibiotic Research & Development Partnership (GARDP), the Drugs for Neglected Diseases Initiative (DNDi), and the South African Medical Research Council (SAMRC) to address antimicrobial resistance (AMR) by accelerating the use of diagnostics.
Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/1971
Global Infectious Disease Diagnostics Market: Opportunities
Players in the market should expect profitable growth possibilities as a result of public and private measures to combat infectious diseases. For example, the Department of Health and Human Services announced in February 2020 that the city of Austin will receive a federal funding of $750,000 to help combat the spread of HIV/AIDS in Texas, United States.
Global Infectious Disease Diagnostics Market: Restraints
The market’s expansion is likely to be hampered by a lack of knowledge and adoption of diagnostic services in emerging markets. According to UNAIDS’ GLOBAL AIDS UPDATE 2019, fewer than 25% of people living with HIV in Madagascar, Mauritius, and South Sudan are aware of their status.
Key Takeaways:
The cell cultures segment of the worldwide infectious disease diagnostics market was worth US$ 362.3 million in 2018, and is predicted to grow at an annual rate of 8.3% to US$ 747.4 million by 2027. Cell culture, which involves growing bacteria in a laboratory setting to identify them, can be used to diagnose a variety of infections.
In terms of volume, the STDs sector dominated the worldwide infectious disease diagnostics market in 2018, accounting for 32.8 percent of the market, followed by CNS infection and respiratory infections The segment’s rise is being fuelled by the rising prevalence of sexually transmitted diseases. Gonorrhea, Chlamydia, Syphilis, Herpes, Hepatitis (HBV), and Human Immunodeficiency Virus are the most frequent of the 20 STDs (HIV). For example, according to Centers for Disease Control and Prevention (CDC), in year 2016, 1,598,354 cases of Chlamydia trachomatis infection were reported in the U.S., corresponding to 497.3 cases per 100,000 in 2015.
The diagnostic centres segment of the worldwide infectious disease diagnostics market was worth US$ 462.1 million in 2018 and is predicted to grow at an annual rate of 8.5 percent to US$ 958.7 million by 2027. Central diagnostic laboratories are well-equipped with the most up-to-date diagnostic equipment and have ample resources to perform a variety of tests.
Market Trends
The limited number of existing diagnostic tests for infectious disorders necessitates the use of combination diagnosis, which entails the use of numerous tests. The practise of diagnosing an illness using many tests is becoming increasingly prevalent.
Because of rising healthcare costs, the market in North America is likely to grow significantly. According to the Centers for Medicare & Medicaid Services (CMS), health spending in the United States is expected to expand at a 5.5 percent annual pace from 2018 to 2027, reaching almost US$ 6.0 trillion. However, the reimbursement scenario for diagnostic tests is comparatively poorer.
Global Infectious Disease Diagnostics Market: Competitive Landscape
Becton Dickinson & Company, Cepheid, Inc., Abbott Laboratories, BioMerieux SA, Hologic, Inc., Danaher Corporation, Thermo Fisher Scientific, Inc., Roche Diagnostics, Alera Inc., DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc. are some of the major players in the global infectious disease diagnostics market.
Global Infectious Disease Diagnostics Market: Key Developments
Chembio Diagnostics, Inc., a point-of-care diagnostics company specialising in infectious diseases, has completed the technical feasibility phase of a potential companion/compatible diagnostic test developed in collaboration with Shire Human Genetic Therapies, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
March 2020: GenMark Diagnostics, Inc., a provider of automated, multiplex molecular diagnostic testing systems, submitted an Emergency Use Authorization to the U.S. Food and Drug Administration (FDA) for its ePlex SARS-CoV-2 Test
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/1971
Segmentation
-
By Technique
-
ELISA
-
Polymerase Chain Reaction
-
Immunoassays
-
Cell Cultures
-
Others
-
-
By Disease Indication
-
CNS Infection
-
Meningitis
-
Brain Abscess
-
-
Diarrhoeal Disease
-
Shigellosis
-
Cholera
-
Enteric/Typhoid Fever
-
-
Respiratory Infections
-
Tuberculosis
-
Influenza
-
Bronchitis
-
-
Blood Infections
-
Malaria
-
Dengue
-
Infectious Mononucleosis
-
Other
-
-
STDs
-
Chlamydia
-
AIDS
-
Syphilis
-
Others
-
-
By End User
-
Hospitals
-
Diagnostic Centers
-
Clinics
-
Government Organizations
-
-
By Region
-
North America
-
Latin America
-
Europe
-
Asia Pacific
-
Middle East
-
Africa
-
-
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
